P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	J. Senapati, J. Ishizawa, H. A. Abbas, S. Loghavi, G. Borthakur, G. C. Issa, S. I. Dara, R. Pourebrahim, N. Daver, E. J. Jabbour, S. M. Kornblau, N. Pemmaraju, G. Garcia-Manero, F. Ravandi, M. Muftuoglu, J. Khoury, C. DiNardo, M. Andreeff
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845192.65192.c0

Similar Items

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
by: Jayastu Senapati, et al.
Published: (2023-06-01)

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
by: M. Yilmaz, et al.
Published: (2022-06-01)

P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Jayastu Senapati, et al.
Published: (2023-08-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN
by: T. Abuasab, et al.
Published: (2022-06-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, CA, et al.
Published: (2022)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2021)

P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY
by: T. Abuasab, et al.
Published: (2022-06-01)

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: J. Senapati, et al.
Published: (2022-06-01)

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
by: Varsha Ananthapadmanabhan, et al.
Published: (2022-07-01)

P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES
by: Jayastu Senapati, et al.
Published: (2023-08-01)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
by: Mahesh Swaminathan, et al.
Published: (2021-04-01)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: S. Venugopal, et al.
Published: (2022-06-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
by: Danielle Hammond, et al.
Published: (2023-09-01)

P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA
by: A. Bazinet, et al.
Published: (2022-06-01)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2023)

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
by: Abhishek Maiti, et al.
Published: (2020-06-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
by: Courtney D. DiNardo, et al.
Published: (2024-07-01)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
by: Fadi Haddad, et al.
Published: (2023-08-01)

Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
by: Rabia Shahswar, et al.
Published: (2023-07-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
by: Prajwal Boddu, et al.
Published: (2017-08-01)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
by: Xiao-Hua Luo, et al.
Published: (2023-08-01)

P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML
by: J. Senapati, et al.
Published: (2022-06-01)

P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: A. Bazinet, et al.
Published: (2022-06-01)

3032 MKit: Pilot Results of Primary Prevention Sexual Violence WebApp
by: Michelle Munro-Kramer, et al.
Published: (2019-03-01)

P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS
by: F. Haddad, et al.
Published: (2022-06-01)

Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
by: Thao M. Nguyen, et al.
Published: (2024-01-01)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
by: S. P. Desikan, et al.
Published: (2022-06-01)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
by: Linyu Yuan, et al.
Published: (2023-08-01)

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS
by: S. Venugopal, et al.
Published: (2022-06-01)

Maxillofacial Injuries: A Retrospective Study of 576 Cases
by: Dhirendra Srivastava, et al.
Published: (1989-02-01)

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
by: Yan-Yan Li, et al.
Published: (2024-01-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
by: Katie Fooks, et al.
Published: (2022-12-01)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01)